Active Glioblastoma Clinical Trials

Data from ClinicalTrials.gov · Privacy-First Design · No Account Required · No Health Data Stored

Why Consider a Glioblastoma (GBM) Clinical Trial?

• Find Trials That Fit — Browse recruiting Glioblastoma (GBM) trials pulled directly from ClinicalTrials.gov — updated continuously so you always see real, active studies.
• No Medical Jargon — Eligibility criteria are rewritten into plain yes-or-no questions. It's always okay to answer "not sure" — your doctor can help fill in the rest.
• See How Well You Match — Get a clear picture of how closely a trial fits your situation, so you know which ones are worth bringing to your oncologist.
• Ready for Your Appointment — Generate a printable or emailable summary for your next visit. A caregiver can send it to your doctor ahead of time.

How It Works

1. Share a Few Details — Enter your Glioblastoma (GBM) type, stage, and location. No personal health information is required or stored.
2. Answer Yes-or-No Questions — We rewrite complex eligibility criteria into plain language. "Not sure" is always a valid answer.
3. Bring Results to Your Doctor — Get a printable summary with the NCT ID, match assessment, and questions to ask your oncologist.

Free · No account · Nothing you enter is stored

Glioblastoma (GBM) Clinical Trial FAQ

What new treatments for glioblastoma are in clinical trials right now?

Current GBM trials are testing: CAR-T therapies targeting tumor antigens (EGFRvIII, IL13Rα2, B7-H3, GD2), oncolytic viruses delivered directly into the tumor (DNX-2401, C134), personalized neoantigen vaccines, convection-enhanced delivery of immunotoxins, novel checkpoint inhibitor combinations, antibody-drug conjugates, and TTFields combined with systemic therapy. Several trials also explore re-irradiation approaches for recurrence.

Does MGMT methylation status affect which glioblastoma trials I qualify for?

Yes. MGMT promoter methylation is the most important predictive biomarker in GBM — it predicts better response to temozolomide. Some trials specifically enroll MGMT-unmethylated patients (who respond poorly to standard therapy and may benefit most from novel approaches), while others enroll all GBM patients regardless of MGMT status. Your neuro-oncologist can interpret your pathology report.

Are there glioblastoma trials for patients who had surgery but cannot receive standard radiation?

Some trials accept patients who are unable to complete standard chemoradiation due to performance status, tumor location, or patient choice. Eligibility requirements vary significantly by study. It is worth discussing your specific situation with a neuro-oncologist at a major academic center, as they are more likely to know about trials with broader eligibility.

Can I join a GBM trial at the time of first recurrence?

Yes — recurrent GBM trials are among the most active in neuro-oncology. First recurrence is often the best window for trial participation because patients generally still have adequate performance status. Bevacizumab, lomustine, and tumor-treating fields are established options for recurrence, and trials testing novel agents at first recurrence are actively enrolling.

What does EGFRvIII mean, and are there GBM trials for it?

EGFRvIII is a mutant form of the EGFR protein found in about 25–30% of GBMs that results from a specific deletion and is not present on normal cells. It has been a promising target for CAR-T cell therapy and antibody-drug conjugates. Several trials have targeted EGFRvIII; while earlier versions had mixed results, next-generation EGFRvIII-targeted agents are in active trials. Ask your neuro-oncologist whether your tumor was tested for EGFRvIII.

Explore Other Cancer Trial Guides

• Brain Cancer — Brain cancer trials are testing IDH inhibitors, tumor-treating fields (TTFields), CAR-T therapies, and oncolytic viruses — with studies available for glioblastoma, grade 2/3 glioma, and brain metastases.
• Lung Cancer — Lung cancer is the leading cause of cancer-related death worldwide. Recruiting clinical trials are testing new immunotherapies, targeted therapies, and combination regimens for NSCLC and SCLC patients.
• Melanoma — Melanoma trials are studying next-generation checkpoint inhibitors, tumor-infiltrating lymphocyte (TIL) therapy, and BRAF/MEK targeted combinations — including adjuvant options for resected disease.
• Head and Neck Cancer — Head and neck cancer trials are testing PD-1/PD-L1 checkpoint inhibitors, cetuximab combinations, and organ-preservation strategies for squamous cell carcinoma of the oral cavity, oropharynx, larynx, and hypopharynx.